Graphite Bio Announces Upcoming Presentation at 49th Annual Sickle Cell Disease Association of America National Convention

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $GRPH #GraphiteBio--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced an abstract related to the company’s sickle cell disease (SCD) research has been accepted for poster presentation...

Click to view original post